The US Food and Drug Administration has turned down approval of Portola Pharmaceuticals’ (Nasdaq: PTLA) anticoagulant antidote product for the time being, sending the company’s shares down 11% to $23.69 in regular trading on Wednesday, and the stock was 17.7% lower at $19.50 in pre-market trading today.
The FDA issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for AndexXa (andexanet alfa).
An FDA-designated Breakthrough Therapy, AndexXa is in development for patients treated with a direct (apixaban, Bristol-Myers and Pfizer’s Eliquis, rivaroxaban, Bayer’s Xarelto, or edoxaban) or indirect (enoxaparin) Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze